TScan Therapeutics, Inc. Profile Avatar - Palmy Investing

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic m…

Biotechnology
US, Waltham [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

TScan Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of TCRX's Analysis
CIK: 1783328 CUSIP: 89854M101 ISIN: US89854M1018 LEI: - UEI: -
Secondary Listings
TCRX has no secondary listings inside our databases.